Our study not only confirmed the prognostic role of AR in all HER2+ nonmetastatic breast IDCs but also confirmed the favorable prognostic value of AR in HER2+HR− nonmetastatic breast cancers. The gene discussed is ERBB2; the disease is breast cancer.